Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative ad...
Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France
4 Oct 2019
Using PARP inhibitors to improve quality of life for patients with metastatic br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
3 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
2 Oct 2019
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early tripl...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
29 Sep 2019
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
29 Sep 2019
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA
29 Sep 2019
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenop...
Prof George Sledge - Stanford Health Care, Stanford, USA
29 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
29 Sep 2019
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postme...
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
29 Sep 2019
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-po...
Prof George Sledge - Stanford Health Care, Stanford, USA
29 Sep 2019
Comment: CDK4/6 inhibitors in advanced breast cancer
Prof Nadia Harbeck - University of Munich, Munich, Germany
29 Sep 2019
